| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJM199005103221901 |
| P698 | PubMed publication ID | 2139173 |
| P50 | author | Fred Valentine | Q42536867 |
| P2093 | author name string | McLaren C | |
| Laverty M | |||
| Reichman RC | |||
| Seidlin M | |||
| Lambert JS | |||
| Pettinelli C | |||
| Knupp C | |||
| Morse GD | |||
| Plank CS | |||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| phase I clinical trial | Q5452194 | ||
| P304 | page(s) | 1333-1340 | |
| P577 | publication date | 1990-05-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial | |
| P478 | volume | 322 |
| Q28316326 | (-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro |
| Q36335275 | 7 The management of HIV disease in pregnancy |
| Q40882776 | A checklist for evaluation of HIV-infected patients |
| Q51749731 | A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. |
| Q36922522 | A ten-year analysis of the incidence and risk factors for acute pancreatitis requiring hospitalization in an urban HIV clinical cohort |
| Q44080147 | A woman with didanosine retinopathy and non-cirrhotic portal hypertension |
| Q40792339 | AAEM minimonograph #41: neuromuscular diseases associated with HIV-1 infection |
| Q28316960 | Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia |
| Q45752028 | Anti-human immunodeficiency virus drug combination strategies |
| Q28323830 | Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells |
| Q71828771 | Antiretroviral therapy |
| Q35184579 | Antiretroviral-associated liver injury |
| Q67514516 | Antiviral agents |
| Q40487963 | Antiviral therapy in human immunodeficiency virus infections. Current status (Part II). |
| Q36070394 | Antiviral therapy: current concepts and practices |
| Q50119987 | Assessing the accuracy of drug information responses from drug information centers |
| Q51147411 | Assessing the needs and quality of life of patients with HIV infection: development of the HIV Overview of Problems-Evaluation System (HOPES) |
| Q39473876 | Bioavailability of once- and twice-daily regimens of didanosine in human immunodeficiency virus-infected children |
| Q36060912 | Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study |
| Q40907967 | Characterization of T lymphocyte subset alterations by flow cytometry in HIV disease |
| Q34023081 | Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity |
| Q41619569 | Clinical pharmacokinetics of stavudine |
| Q67485423 | Combination Therapy for HIV Infection: Getting Closer |
| Q40886850 | Comparative pharmacokinetics of antiviral nucleoside analogues |
| Q45751587 | Consequences of ddI-induced reduction of acute SIVmac251 virus load on cytokine profiles in cynomolgus macaques |
| Q40381501 | Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele |
| Q35174403 | Correlations Between theIn VitroandIn VivoActivity of Anti-HIV Agents: Implications for Future Drug Deyelopment |
| Q37034589 | Current clinical treatments of AIDS. |
| Q31952613 | Data of pre-clinical and early clinical trials of acriflavine and hydroxy-methyl-ellipticine reviewed, enriched by the experience of their use for 18 months to 6 years in combinations with other HIV1 virostatics |
| Q28323773 | Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization |
| Q35839770 | Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy. |
| Q35174341 | Development of Inhibitors of Reverse Transcriptase and Protease as Therapeutics Against HIV Infection |
| Q33795945 | Development of a model longitudinal data base to measure outcomes and quality of care among persons with AIDS. |
| Q35255870 | Didanosine |
| Q45776455 | Didanosine administration in a human immunodeficiency virus-positive renal transplant patient |
| Q35124724 | Didanosine measurement by radioimmunoassay |
| Q28327854 | Didanosine therapy in patients intolerant of or failing zidovudine therapy |
| Q44780075 | Didanosine treatment of haemophilic patients infected with HIV. |
| Q35530740 | Didanosine, a new antiretroviral drug. A review |
| Q46987157 | Didanosine-induced retinopathy in adults can be reversible |
| Q35331251 | Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection |
| Q45860738 | Dideoxyinosine in Children with Symptomatic Human Immunodeficiency Virus Infection |
| Q33900606 | Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells |
| Q39037792 | Dosing nucleoside reverse transcriptase inhibitors in adults receiving continuous veno-venous hemofiltration |
| Q34589705 | Drug induced acute pancreatitis: does it exist? |
| Q34409038 | Drug induced acute pancreatitis: incidence and severity |
| Q41158885 | Drugs, sex and HIV : a mathematical model for New York City |
| Q40447292 | Early versus delayed treatment of HIV infection. Zidovudine should be given before symptoms develop. |
| Q35114198 | Effect of fluconazole on pharmacokinetics of 2',3'-dideoxyinosine in persons seropositive for human immunodeficiency virus |
| Q42614912 | Effect of time of food administration on the bioavailability of didanosine from a chewable tablet formulation |
| Q35821454 | Effects of U-75875, a peptidomimetic inhibitor of retroviral proteases, on simian immunodeficiency virus infection in rhesus monkeys |
| Q39867349 | Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis |
| Q52028330 | Effects of light on T-cells in HIV-infected subjects are not dependent on history of seasonal affective disorder. |
| Q40909668 | Effects of zidovudine (AZT) and dideoxyinosine (ddI) on human trophoblast cells |
| Q33747461 | Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells |
| Q70658656 | Evaluation of a dual-color flow cytometry immunophenotyping panel in a multicenter quality assurance program |
| Q67828440 | Evaluation of hiv p24 antigen, beta2-microglobulin, neopterin, soluble cd4, soluble cd8, and soluble interleukin-2 receptor levels in patients with aids or aids-related complex treated with 2′,3′-dideoxyinosine (ddl) |
| Q28378991 | Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication |
| Q34727696 | Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy |
| Q40484511 | Future Therapies in the Management of Critically Ill, AIDS Patients |
| Q35836636 | Ganciclovir antagonizes the anti-human immunodeficiency virus type 1 activity of zidovudine and didanosine in vitro |
| Q36889730 | Gastrointestinal emergencies in HIV infection |
| Q41240964 | Gastrointestinal manifestations |
| Q36674581 | HIV-Specific Treatment |
| Q37988382 | HIV-associated sensory neuropathy: risk factors and genetics |
| Q36537911 | HIV/AIDS pathogenesis and treatment: new twists and turns |
| Q36646145 | Hematologic Effects of AIDS Therapies |
| Q45789678 | High-performance liquid chromatography and photoaffinity crosslinking to explore the binding environment of nevirapine to reverse transcriptase of human immunodeficiency virus type-1 |
| Q35143082 | Hyperlactataemia syndromes associated with HIV therapy |
| Q43787821 | Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study |
| Q36597486 | Immunologic issues in anti-retroviral therapy |
| Q41375344 | Immunomodulatory and antiviral activities of 2',3'-dideoxy-beta-L-cytidine and 2',3'-dideoxy-beta-L-5-fluorocytidine |
| Q23915942 | Immunotoxicity of 2',3'-dideoxyinosine in female B6C3F1 mice |
| Q35862757 | Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials |
| Q42801263 | Improved uptake and retention of lipophilic prodrug to improve treatment of HIV. |
| Q28318476 | In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations |
| Q84696065 | In vitro studies of the toxicity of nucleoside analogues used in the treatment of HIV infection |
| Q67474997 | Influence on survival of p24 antigen levels in patients with AIDS or advanced AIDS related complex treated with zidovudine |
| Q28323983 | Inhibition of HIV-reverse transcriptase activity by some phloroglucinol derivatives |
| Q34264407 | Inhibition of immune functions by antiviral drugs |
| Q37202730 | Is it time for a comprehensive aids medical center? |
| Q45859635 | Kinetic interaction of human immunodeficiency virus type 1 reverse transcriptase with the antiviral tetrahydroimidazo[4,5,1-jk]-[1,4]-benzodiazepine-2-(1H)-thione compound, R82150 |
| Q40626125 | Management of antiretroviral drug therapy in human immunodeficiency virus infection |
| Q36640801 | Markers predicting progression of human immunodeficiency virus-related disease |
| Q34402837 | Metabolism of 2',3'-dideoxyinosine (ddI) in human blood |
| Q34282667 | Mitochondrial dna depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors |
| Q35136214 | Mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor therapy: experimental clarifications and persistent clinical questions |
| Q41850795 | Neural networks in the assessment of HIV immunopathology |
| Q38960541 | Neuroepidemiology of HIV infection |
| Q37166318 | Neurologic and psychiatric manifestations of HIV disease |
| Q41240954 | Neurologic manifestations of HIV infection. |
| Q33607809 | Neuromuscular complications of human immunodeficiency virus infection and antiretroviral therapy |
| Q68228479 | Nucleoside Therapy for HIV Infection — Some Answers, Many Questions |
| Q35071456 | Nucleoside analogues and neuropathy in the era of HAART. |
| Q43906491 | Pancreatic disorders in pediatric acquired immune deficiency syndrome |
| Q40562921 | Pancreatic lesions in HIV-infected patients |
| Q24634681 | Pathogenesis of human immunodeficiency virus infection |
| Q39412870 | Perceived needs and unmet needs for formal services among people with HIV disease |
| Q77764406 | Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management |
| Q45753981 | Pharmaceutical properties of related calanolide compounds with activity against human immunodeficiency virus |
| Q40088469 | Pharmacokinetic-interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus |
| Q41898084 | Pharmacokinetics of co-administered didanosine and stavudine in HIV-seropositive male patients |
| Q45777843 | Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus |
| Q33377921 | Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection |
| Q37785520 | Pharmacologic effects on mitochondrial function |
| Q28321882 | Phase I study of 2′-3′-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine |
| Q58416812 | Population Pharmacokinetic Analysis of Didanosine (2′,3′-Dideoxyinosine) Plasma Concentrations Obtained in Phase I Clinical Trials in Patients with AIDS or AIDS-Related Complex |
| Q33209838 | Predicting anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-ones: computational approach using reformed eccentric connectivity index |
| Q43782897 | Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study |
| Q37669874 | Primary care and HIV disease |
| Q30398286 | Pseudogout Associated Hip Pain in a Patient with HIV Infection |
| Q36482233 | Pyrimidine nucleoside depletion sensitizes to the mitochondrial hepatotoxicity of the reverse transcriptase inhibitor stavudine |
| Q35129433 | Quantitation of intracellular zidovudine phosphates by use of combined cartridge-radioimmunoassay methodology. |
| Q42622850 | Randomized study of two doses of didanosine in children infected with human immunodeficiency virus |
| Q43413064 | Reverse transcriptase genotype and antiretroviral susceptibility of human immunodeficiency virus isolates from patients with advanced disease treated with didanosine: correlation with virologic response and survival |
| Q37138780 | Rheumatic conditions in human immunodeficiency virus infection |
| Q45767398 | Safety of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in patients with human immunodeficiency virus infection: a pilot study |
| Q35116326 | Safety, pharmacokinetics, and antiviral activity of A77003, a C2 symmetry-based human immunodeficiency virus protease inhibitor |
| Q37977579 | Screening for new agents |
| Q28326720 | Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro |
| Q47332701 | Synthesis and antitumor evaluation of acyclic 1-[omega-(N'-2-chloroethyl-N'-nitrosoureido)alkyl]thymidine nucleoside analogues |
| Q42182127 | Synthesis and antiviral evaluation of novel 4'-trifluoromethylated 5'-deoxyapiosyl nucleoside phosphonic acids |
| Q41522072 | Synthesis of novel 2',3'-difluorinated 5'-deoxythreosyl phosphonic acid nucleosides as antiviral agents |
| Q57167986 | Synthesis of the 6′-Fluoro Derivatives of Carbocyclic 2′,3′-Dideoxy-3′-oxa-adenosine |
| Q28320896 | Targeting antiretroviral nucleoside analogues in phosphorylated form to macrophages: in vitro and in vivo studies |
| Q31391473 | Temporal development of 2',3'-dideoxyinosine (ddI)-induced peripheral myelinopathy |
| Q30429401 | The HIV global pandemic: the development and emerging implication |
| Q52882917 | The effects of immune status and race on health service use among people with HIV disease. |
| Q34122352 | The management of the clinical complications of antiretroviral therapy |
| Q67734517 | Treatment of HIV Infection — Progress in Perspective |
| Q40623726 | Treatment of HIV infection in infancy. |
| Q41175137 | Treatment of HIV infection. Tolerability of commonly used antiretroviral agents |
| Q44937514 | Treatment of HIV infection: the antiretroviral nucleoside analogues. Introduction |
| Q35232021 | Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: adverse effects |
| Q35232016 | Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: combination therapy |
| Q57334318 | Uridine supplementation antagonizes zalcitabine-induced microvesicular steatohepatitis in mice |
| Q35172760 | Viruses, chemotherapy and immunity |
Search more.